knowledge -WSS

knowledge

author：fashion 2025-10-02 19:21:16 - browse：3

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Eight reasons why you should get an updated Covid vaccine

knowledge

focus

WSS

What the Wegovy shortage looks like for doctors — and for patients

STAT Readout: Today's biotech news includes Sana and Amylyx

Massive project maps cells in human brain in unprecedented detail

Nick Jonas talks about managing diabetes along with his career

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Takeaways from AdvaMed, the largest medical devices conference

focus

knowledge

focus

Bright Health sells Medicare Advantage business to Molina

How should state employee insurance handle Wegovy?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New air purifier tech could be key to improving indoor air quality

DIEP, the 'gold standard' of breast reconstruction, is under threat

BioMarin wins approval for gene therapy to treat hemophilia A

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare details structure of new drug price negotiation program

Novavax promises a turnaround & Lilly roils the obesity market

A fraught question for the kids of Alzheimer’s: Is it coming for us?

hotspot

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

ChatGPT in medicine: STAT answers readers' burning questions

United colonoscopy coverage change 'may cost lives,' doctors say

BioMarin wins approval for gene therapy to treat hemophilia A

Cancer cells are shown to suck energy source from immune cells

A revolution in caring for preterm infants

knowledge

Wikipedia

focus

explore